Globenewswire·2025-11-25 09:00Core Insights - Autolus Therapeutics plc has received draft guidance from NICE recommending AUCATZYL (obecabtagene autoleucel) for use in the NHS in England and Wales for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) [1][2] - AUCATZYL is expected to be launched imminently in England and Wales, with plans to pursue access through the Scottish Medical Consortium [1][2] - The therapy has received conditional marketing authorization from the UK MHRA based on the results of the FELIX study, which demonstrated its efficacy [2][4] Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases [3] - The company utilizes proprietary T cell programming technologies to create targeted and controlled therapies [3] Product Details - AUCATZYL is a CD19 CAR T cell therapy designed to improve clinical activity and safety compared to existing therapies [4] - It was approved by the FDA in November 2024 and received conditional marketing authorization from the MHRA and EMA in 2025 [4]